[HTML][HTML] Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury
DE Hricik, P Nickerson, RN Formica, ED Poggio… - American Journal of …, 2013 - Elsevier
Noninvasive biomarkers are needed to assess immune risk and ultimately guide therapeutic
decision-making following kidney transplantation. A requisite step toward these goals is
validation of markers that diagnose and/or predict relevant transplant endpoints. The Clinical
Trials in Organ Transplantation-01 protocol is a multicenter observational study of
biomarkers in 280 adult and pediatric first kidney transplant recipients. We compared and
validated urinary mRNAs and proteins as biomarkers to diagnose biopsy-proven acute …
decision-making following kidney transplantation. A requisite step toward these goals is
validation of markers that diagnose and/or predict relevant transplant endpoints. The Clinical
Trials in Organ Transplantation-01 protocol is a multicenter observational study of
biomarkers in 280 adult and pediatric first kidney transplant recipients. We compared and
validated urinary mRNAs and proteins as biomarkers to diagnose biopsy-proven acute …